First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with  BRCA2  and  PTEN  alterations | Zendy

Omura Minami | Zendy; Kosaka Takeo | Zendy; Aimono Eriko | Zendy; Nakamura Kohei | Zendy; Hongo Hiroshi | Zendy; Mikami Shuji | Zendy; Nishihara Hiroshi | Zendy; Oya Mototsugu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

First successful case of platinum‐based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

Author(s) -

Omura Minami,

Kosaka Takeo,

Aimono Eriko,

Nakamura Kohei,

Hongo Hiroshi,

Mikami Shuji,

Nishihara Hiroshi,

Oya Mototsugu

Publication year - 2022

Publication title -

iju case reports

Language(s) - English

Resource type - Journals

ISSN - 2577-171X

DOI - 10.1002/iju5.12383

Subject(s) - pten , prostate cancer , medicine , oncology , chemotherapy , dna damage repair , prostate , cancer , cancer research , bioinformatics , pi3k/akt/mtor pathway , gene , biology , dna repair , apoptosis , genetics

Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation We report the case of a Japanese patient with advanced castration‐resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research